Further to the announcement made on 7 March 2025, Avacta Group plc (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that all closing conditions to the sale of the entire issued share capital of Launch Diagnostics Holdings Limited and its subsidiaries, its UK-headquartered and largest diagnostics unit, to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U, have been satisfied and completion of the sale took place yesterday.